$30.15

-0.34 (-1.12%)

Weekly Expected Move ±6.2%

$26 $28 $30 $32 $34

NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 42 · $1.7B mcap · 50M float · 1.78% daily turnover · Short 61% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE

46.5 / 100

NoneWeakNarrowWide

Primary source: Switching Costs · ROIC: 41.8% · 5Y Avg: 7.3%

Cost Advantage

Intangibles

Switching Cost

Network Effect

Scale

The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. HRMY shows a Weak competitive edge (46.5/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Switching Costs. ROIC of 41.8% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets

Low

$31

Avg Target

$45

High

Based on 10 analyst ratings (12 mo)

Analyst Recommendations

Strong Buy: 0Buy: 9Hold: 2Sell: 2Strong Sell: 0

Rating Summary

ConsensusBuy

Avg Target$31.00

Analysts1

Price Target Change History

Date	Firm	Analyst	Old	New	Change	Upside @ Call	Stock@Call
2026-02-23	Deutsche Bank	—	Initiated	$31	—	+6.3%	$29.16
2026-02-19	Mizuho Securities	—	$46	$50	+4	+41.7%	$35.28
2026-02-11	UBS	Youn Shim	$43	$46	+3	+21.3%	$37.93
2026-01-08	Truist Financial	—	Initiated	$45	—	+19.8%	$37.55
2025-12-01	Mizuho Securities	—	$36	$46	+10	+30.3%	$35.29
2025-11-24	Oppenheimer	Andreas Argyrides	$56	$62	+6	+80.7%	$34.31
2025-10-29	Mizuho Securities	—	$52	$36	-16	+21.5%	$29.64
2025-10-15	UBS	—	$48	$43	-5	+60.2%	$26.84
2025-09-25	H.C. Wainwright	—	Initiated	$55	—	+103.4%	$27.04
2025-07-10	Goldman Sachs	Corinne Johnson	$28	$33	+5	-3.9%	$34.33
2025-04-28	UBS	—	$56	$48	-8	+63.5%	$29.36
2024-10-30	Goldman Sachs	Corinne Jenkins	Initiated	$28	—	-32.5%	$41.49
2024-10-10	Mizuho Securities	Graig Suvannavejh	$42	$52	+10	+54.8%	$33.60
2024-09-10	UBS	Ashwani Verma	Initiated	$56	—	+51.8%	$36.89
2024-08-08	Mizuho Securities	Graig Suvannavejh	Initiated	$42	—	+25.2%	$33.55
2024-06-24	Oppenheimer	Francois Brisebois	Initiated	$56	—	+84.3%	$30.39
2024-05-01	Needham	Ami Fadia	Initiated	$52	—	+71.2%	$30.37
2024-04-30	Raymond James	Danielle Brill	Initiated	$37	—	+19.7%	$30.91
2022-10-14	Jefferies	Chris Howerton	Initiated	$61	—	+28.1%	$47.63

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

May 22, 2026

DCF

ROE

ROA

D/E

P/E

P/B

The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. HRMY receives an overall rating of A. Strongest factors: DCF (5/5), ROE (4/5), ROA (5/5). Areas of concern: D/E (2/5).

Rating Change History

Date	From	To
2026-04-27	A-	A
2026-04-01	A	A-
2026-02-26	A+	A
2026-02-24	A-	A+
2026-02-18	B+	A-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 79 Grade A+

Profitability

Balance Sheet

Earnings Quality

Growth

Value

Momentum

Safety

100

Cash Flow

100

The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. HRMY scores highest in Safety (100/100) and lowest in Growth (53/100). An overall grade of A+ places HRMY among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score

4.50

Safe Zone

Piotroski F-Score

6/9

✓ ✓ ✗ ✓ ✓ ✓ ✗ ✗ ✓

Beneish M-Score

-3.07

Unlikely Manipulator

Ohlson O-Score

-10.48

Bankruptcy prob: 0.0%

Low Risk

Credit Rating

AA+

Score: 91.6/100

Trend: Deteriorating

Earnings Quality

75/100

OCF/NI: 2.35x

Accruals: -17.3%

The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. HRMY scores 4.50, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. HRMY scores 6/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. HRMY's score of -3.07 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. HRMY's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. HRMY receives an estimated rating of AA+ (score: 91.6/100), with a deteriorating trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). HRMY's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E

11.97x

PEG

-2.01x

P/S

1.94x

P/B

1.91x

P/FCF

4.82x

P/OCF

4.81x

EV/EBITDA

4.76x

EV/Revenue

1.24x

EV/EBIT

5.34x

EV/FCF

3.25x

Earnings Yield

8.84%

FCF Yield

20.76%

Shareholder Yield

0.00%

Graham Number

$28.73

Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 12.0x earnings, HRMY trades at a reasonable valuation. An earnings yield of 8.8% exceeds typical risk-free rates, suggesting equities are being compensated for risk. Graham's intrinsic value formula yields $28.73 per share, 5% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden

0.737

NI / EBT

Interest Burden

0.950

EBT / EBIT

EBIT Margin

0.231

EBIT / Rev

Asset Turnover

0.792

Rev / Assets

Equity Multiplier

1.485

Assets / Equity

ROE

19.0%

The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. HRMY's ROE of 19.0% is driven by Asset Turnover (0.792), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate

0.00%

Fair P/E

8.50x

Intrinsic Value

$21.06

Price/Value

1.33x

Margin of Safety

-33.01%

Premium

33.01%

Assessment

Overvalued

Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with HRMY's realized 0.0% 3-year EPS CAGR — what the company actually delivered, not what analysts hope for. HRMY trades at a 33% premium to its adjusted intrinsic value of $21.06, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 8.5x compares to the current market P/E of 12.0x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1447 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price

$30.15

Median 1Y

$25.20

5th Pctile

$10.12

95th Pctile

$63.08

Ann. Volatility

53.6%

Analyst Target

$31.00

25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

Executive	Salary	Stock	Total
Jeffrey M. Dayno, M.D. President and Chief Executive Officer	$743,600	$1,976,520	$7,899,535
Adam Zaeske EVP and Chief Commercial Officer	$376,923	$852,000	$3,664,228
Sandip Kapadia EVP and Chief Financial Officer and Chief Administrative Officer	$522,834	$718,389	$3,204,319
Jeffrey Dierks EVP mer EVP and Chief Commercial Officer	$132,263	$511,235	$2,346,945
Kumar Budur EVP and Chief Medical & Scientific Officer	$598,000	$404,807	$2,279,439
Andrew Serafin EVP, Chief Strategy Officer	$439,208	$395,304	$2,009,277

CEO Pay Ratio

581:1

CEO-to-Employee Pay Ratio

CEO Total Comp: $7,899,535

Avg Employee Cost (SGA/emp): $13,602

Employees: 20,000

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees

20,000

+7362.7% YoY

Revenue / Employee

$43,423

Rev: $868,453,000

Profit / Employee

$7,934

NI: $158,687,000

SGA / Employee

$13,602

Avg labor cost proxy

R&D / Employee

$9,480

Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
ROE	23.9%	27.3%	24.4%	34.3%	41.0%	1.1%	61.6%	64.3%	68.0%	51.2%	29.6%	31.7%	26.4%	28.2%	25.8%	27.1%	32.1%	33.0%	20.8%	19.0%	19.04%
ROA	5.4%	4.4%	8.0%	11.3%	13.5%	36.2%	32.8%	34.2%	36.2%	27.2%	17.4%	18.5%	15.5%	16.5%	16.1%	16.9%	20.0%	20.5%	14.0%	12.8%	12.82%
ROIC	82.2%	97.2%	54.7%	61.9%	65.1%	1.3%	76.8%	78.0%	80.9%	62.3%	46.5%	48.7%	40.4%	39.9%	38.8%	40.5%	47.7%	48.7%	46.0%	41.8%	41.76%
ROCE	19.1%	13.8%	9.3%	12.7%	15.3%	19.8%	20.2%	22.9%	25.8%	33.7%	32.1%	34.1%	30.3%	31.5%	25.4%	26.0%	29.3%	29.4%	22.2%	20.4%	20.40%
Gross Margin	82.8%	81.9%	80.5%	82.8%	82.3%	80.4%	79.0%	82.6%	81.4%	79.8%	74.4%	82.2%	81.4%	77.0%	73.0%	82.7%	81.0%	75.1%	71.9%	79.3%	79.33%
Operating Margin	31.6%	26.1%	31.4%	32.3%	30.9%	10.2%	37.1%	33.9%	34.9%	40.3%	23.9%	33.7%	12.4%	33.2%	27.7%	30.4%	24.0%	27.3%	15.8%	17.3%	17.31%
Net Margin	19.1%	-11.9%	24.9%	25.2%	22.0%	75.0%	37.8%	24.8%	25.6%	24.0%	15.8%	24.8%	6.7%	24.8%	24.6%	24.7%	19.8%	21.2%	9.2%	15.1%	15.08%
EBITDA Margin	38.0%	-0.5%	8.0%	38.4%	36.6%	15.4%	41.9%	41.6%	42.0%	40.5%	36.4%	40.4%	18.6%	39.0%	33.0%	36.3%	29.6%	30.7%	21.2%	22.7%	22.70%
FCF Margin	20.9%	26.2%	32.2%	34.6%	35.8%	38.7%	33.0%	33.5%	32.3%	31.2%	37.6%	33.6%	32.4%	32.3%	30.6%	29.7%	33.5%	35.9%	40.1%	38.0%	38.01%
OCF Margin	21.0%	26.3%	32.3%	34.7%	35.8%	38.8%	33.0%	33.5%	32.4%	31.3%	37.7%	33.7%	32.5%	32.4%	30.8%	29.9%	33.6%	36.0%	40.1%	38.0%	38.03%
ROE 3Y Avg	snapshot only																				23.13%
ROE 5Y Avg	snapshot only																				28.51%
ROA 3Y Avg	snapshot only																				14.57%
ROIC Economic	snapshot only																				12.79%
Cash ROA	snapshot only																				26.89%
Cash ROIC	snapshot only																				1.02%
CROIC	snapshot only																				1.02%
NOPAT Margin	snapshot only																				15.53%
Pretax Margin	snapshot only																				21.97%
R&D / Revenue	snapshot only																				24.96%
SGA / Revenue	snapshot only																				30.51%
SBC / Revenue	snapshot only																				3.61%

Valuation

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
P/E Ratio	71.28	189.51	74.34	60.53	51.13	17.41	18.71	10.55	10.68	13.19	14.75	14.05	15.10	18.95	13.77	12.72	10.21	8.72	13.84	11.31	11.972
P/S Ratio	7.03	8.18	8.42	8.90	8.16	6.76	7.75	4.24	4.28	3.67	3.27	3.13	2.65	3.41	2.80	2.61	2.39	1.96	2.53	1.83	1.941
P/B Ratio	17.02	22.77	13.79	15.80	15.93	14.54	8.43	4.96	5.31	4.94	4.07	4.14	3.72	4.98	3.04	2.95	2.80	2.46	2.52	1.89	1.915
P/FCF	33.56	31.26	26.17	25.73	22.79	17.47	23.53	12.65	13.26	11.75	8.68	9.31	8.16	10.56	9.16	8.77	7.14	5.45	6.31	4.82	4.817
P/OCF	33.43	31.13	26.09	25.66	22.76	17.45	23.50	12.64	13.24	11.74	8.66	9.30	8.13	10.52	9.11	8.72	7.12	5.44	6.31	4.81	4.814
EV/EBITDA	22.58	36.94	46.85	43.01	37.21	27.48	22.71	11.63	11.29	8.27	7.50	7.24	7.14	9.48	7.36	6.96	5.89	5.01	6.60	4.76	4.760
EV/Revenue	6.88	8.05	8.29	8.79	8.05	6.67	7.45	3.96	4.02	3.43	2.99	2.87	2.40	3.17	2.40	2.22	2.02	1.61	1.91	1.24	1.235
EV/EBIT	28.94	53.79	71.89	60.25	50.46	35.55	27.12	13.70	13.07	9.27	8.38	8.04	8.03	10.61	8.21	7.74	6.47	5.50	7.35	5.34	5.339
EV/FCF	32.87	30.78	25.78	25.40	22.50	17.22	22.62	11.82	12.44	10.98	7.95	8.54	7.41	9.83	7.85	7.48	6.03	4.49	4.77	3.25	3.249
Earnings Yield	1.4%	0.5%	1.3%	1.7%	2.0%	5.7%	5.3%	9.5%	9.4%	7.6%	6.8%	7.1%	6.6%	5.3%	7.3%	7.9%	9.8%	11.5%	7.2%	8.8%	8.84%
FCF Yield	3.0%	3.2%	3.8%	3.9%	4.4%	5.7%	4.2%	7.9%	7.5%	8.5%	11.5%	10.7%	12.3%	9.5%	10.9%	11.4%	14.0%	18.3%	15.8%	20.8%	20.76%
Price/Tangible Book	snapshot only																				2.109
EV/OCF	snapshot only																				3.248
EV/Gross Profit	snapshot only																				1.614
Acquirers Multiple	snapshot only																				5.860
Shareholder Yield	snapshot only																				0.00%
Graham Number	snapshot only																				$28.73

Leverage & Solvency

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Current Ratio	1.95	1.95	5.29	5.29	5.29	5.29	5.07	5.07	5.07	5.07	2.75	2.75	2.75	2.75	3.31	3.31	3.31	3.31	3.60	3.60	3.597
Quick Ratio	1.93	1.93	5.21	5.21	5.21	5.21	5.02	5.02	5.02	5.02	2.72	2.72	2.72	2.72	3.27	3.27	3.27	3.27	3.58	3.58	3.576
Debt/Equity	2.00	2.00	1.05	1.05	1.05	1.05	0.48	0.48	0.48	0.48	0.41	0.41	0.41	0.41	0.28	0.28	0.28	0.28	0.28	0.28	0.275
Net Debt/Equity	-0.35	-0.35	-0.21	-0.21	-0.21	-0.21	-0.33	-0.33	-0.33	-0.33	-0.34	-0.34	-0.34	-0.34	-0.43	-0.43	-0.43	-0.43	-0.62	-0.62	-0.616
Debt/Assets	0.45	0.45	0.45	0.45	0.45	0.45	0.28	0.28	0.28	0.28	0.24	0.24	0.24	0.24	0.18	0.18	0.18	0.18	0.19	0.19	0.188
Debt/EBITDA	2.71	3.29	3.62	2.89	2.48	2.01	1.33	1.19	1.08	0.85	0.83	0.79	0.88	0.85	0.78	0.76	0.68	0.68	0.95	1.03	1.027
Net Debt/EBITDA	-0.48	-0.58	-0.71	-0.57	-0.49	-0.40	-0.91	-0.82	-0.74	-0.59	-0.69	-0.65	-0.72	-0.70	-1.22	-1.20	-1.08	-1.07	-2.13	-2.30	-2.296
Interest Coverage	1.91	1.46	1.47	2.30	3.28	4.62	7.68	7.91	7.86	8.89	8.75	9.78	9.47	11.28	11.96	12.74	15.04	15.81	15.43	14.81	14.807
Equity Multiplier	4.39	4.39	2.32	2.32	2.32	2.32	1.67	1.67	1.67	1.67	1.74	1.74	1.74	1.74	1.52	1.52	1.52	1.52	1.46	1.46	1.461
Cash Ratio	snapshot only																				3.075
Debt Service Coverage	snapshot only																				16.611
Cash to Debt	snapshot only																				3.236
FCF to Debt	snapshot only																				1.427
Defensive Interval	snapshot only																				638.3 days

Efficiency & Turnover

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Asset Turnover	0.55	1.01	0.71	0.77	0.85	0.93	0.79	0.85	0.90	0.98	0.78	0.83	0.88	0.92	0.79	0.82	0.85	0.91	0.76	0.79	0.792
Inventory Turnover	10.70	19.39	13.45	14.49	16.00	18.03	19.13	20.52	21.91	24.05	25.10	26.49	27.97	30.14	24.97	25.69	26.64	29.33	31.60	33.59	33.590
Receivables Turnover	10.61	20.47	10.71	11.61	12.78	14.06	9.78	10.53	11.14	12.10	9.03	9.58	10.18	10.58	9.09	9.48	9.83	10.51	9.66	10.00	10.000
Payables Turnover	16.00	10.68	31.22	33.64	37.14	41.84	34.88	37.41	39.95	43.86	11.27	11.89	12.56	13.53	9.96	10.25	10.63	11.71	12.62	13.41	13.415
DSO	34	18	34	31	29	26	37	35	33	30	40	38	36	34	40	39	37	35	38	36	36.5 days
DIO	34	19	27	25	23	20	19	18	17	15	15	14	13	12	15	14	14	12	12	11	10.9 days
DPO	23	34	12	11	10	9	10	10	9	8	32	31	29	27	37	36	34	31	29	27	27.2 days
Cash Conversion Cycle	46	2	50	46	42	37	46	43	40	37	23	21	20	20	18	17	17	16	20	20	20.2 days
Fixed Asset Turnover	snapshot only																				168.246
Operating Cycle	snapshot only																				47.4 days
Cash Velocity	snapshot only																				1.160
Capital Intensity	snapshot only																				1.414

Growth (YoY)

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Revenue	—	4.9%	2.0%	1.0%	54.8%	48.1%	43.4%	42.5%	36.9%	35.2%	32.9%	30.9%	31.5%	25.8%	22.8%	20.6%	17.7%	21.1%	21.5%	20.7%	20.71%
Net Income	—	5.1%	19.3%	4.4%	1.5%	12.3%	4.2%	2.9%	2.4%	-3.2%	-29.0%	-27.3%	-42.6%	-18.7%	12.9%	10.9%	57.3%	51.4%	9.1%	-4.7%	-4.65%
EPS	—	5.4%	18.2%	4.2%	1.4%	11.6%	4.1%	2.9%	2.5%	-2.3%	-25.7%	-22.7%	-39.4%	-15.1%	14.1%	9.1%	54.9%	49.8%	8.2%	-5.1%	-5.06%
FCF	—	7.0%	4.2%	2.6%	1.6%	1.2%	46.9%	38.0%	23.7%	9.1%	51.8%	31.4%	32.0%	30.1%	-0.2%	6.6%	21.6%	34.8%	59.1%	54.4%	54.38%
EBITDA	—	3.8%	1.2%	54.8%	9.9%	64.9%	1.7%	1.4%	1.3%	1.3%	61.5%	52.6%	24.2%	1.6%	0.5%	-2.9%	20.0%	16.5%	7.7%	-1.9%	-1.94%
Op. Income	—	5.4%	3.8%	2.1%	97.1%	51.8%	37.3%	32.3%	33.1%	97.1%	59.8%	53.1%	21.3%	-12.1%	-0.6%	-4.2%	24.6%	28.7%	9.2%	-2.8%	-2.83%
OCF Growth	snapshot only																				53.58%
Asset Growth	snapshot only																				27.26%
Equity Growth	snapshot only																				32.02%
Debt Growth	snapshot only																				32.07%
Shares Change	snapshot only																				0.43%

Growth (CAGR)

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Revenue 3Y	—	—	—	—	—	—	—	—	—	1.3%	78.8%	56.3%	40.7%	36.1%	32.8%	31.0%	28.5%	27.3%	25.6%	24.0%	23.99%
Revenue 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	78.5%	53.5%	41.0%	40.96%
EPS 3Y	—	—	—	—	—	—	—	—	—	3.3%	3.2%	1.5%	71.5%	1.2%	63.3%	48.1%	48.1%	7.5%	-2.8%	-7.1%	-7.15%
EPS 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.5%	1.5%	74.2%	74.18%
Net Income 3Y	—	—	—	—	—	—	—	—	—	3.3%	3.2%	1.5%	70.5%	1.2%	61.4%	46.4%	46.0%	6.1%	-4.4%	-8.4%	-8.40%
Net Income 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.5%	1.5%	74.2%	74.16%
EBITDA 3Y	—	—	—	—	—	—	—	—	—	1.6%	1.1%	77.7%	45.5%	57.0%	62.8%	52.1%	49.8%	39.9%	20.5%	13.3%	13.27%
EBITDA 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	84.8%	59.3%	39.8%	39.81%
Gross Profit 3Y	—	—	—	—	—	—	—	—	—	1.3%	76.3%	54.3%	38.9%	34.0%	30.7%	29.1%	26.6%	25.3%	23.7%	21.7%	21.67%
Gross Profit 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	76.3%	51.5%	38.9%	38.85%
Op. Income 3Y	—	—	—	—	—	—	—	—	—	1.7%	1.2%	84.0%	47.1%	38.0%	29.7%	24.7%	26.2%	30.6%	20.2%	12.5%	12.51%
Op. Income 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	85.1%	63.0%	42.1%	42.13%
FCF 3Y	—	—	—	—	—	—	—	—	—	1.7%	1.3%	87.7%	62.8%	46.0%	30.6%	24.6%	25.7%	24.2%	34.1%	29.3%	29.32%
FCF 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.0%	79.1%	61.2%	61.19%
OCF 3Y	—	—	—	—	—	—	—	—	—	1.7%	1.3%	87.8%	62.8%	45.9%	30.7%	24.7%	25.7%	24.2%	34.1%	29.3%	29.31%
OCF 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.0%	79.1%	61.2%	61.20%
Assets 3Y	—	—	—	—	—	—	—	—	—	84.8%	23.9%	23.9%	23.9%	23.9%	32.1%	32.1%	32.1%	32.1%	23.6%	23.6%	23.57%
Assets 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	56.4%	24.4%	24.4%	24.39%
Equity 3Y	—	—	—	—	—	—	—	—	—	—	68.8%	68.8%	68.8%	68.8%	52.3%	52.3%	52.3%	52.3%	29.3%	29.3%	29.27%
Book Value 3Y	—	—	—	—	—	—	—	—	—	—	66.9%	69.9%	69.8%	68.4%	54.1%	54.1%	54.5%	54.4%	31.4%	31.0%	31.04%
Dividend 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Growth Quality

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Revenue Stability	—	—	—	—	—	0.98	0.99	1.00	1.00	0.98	0.99	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.999
Earnings Stability	—	—	—	—	—	0.80	0.88	0.91	0.89	0.81	0.67	0.68	0.49	0.63	0.62	0.62	0.60	0.72	0.61	0.53	0.529
Margin Stability	—	—	—	—	—	0.99	0.99	0.99	0.99	0.99	0.98	0.98	0.98	0.98	0.98	0.98	0.98	0.97	0.97	0.97	0.971
Rev. Growth Consistency	0.00	0.50	0.50	0.50	0.50	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.000
Earn. Growth Consistency	0.00	0.50	0.50	0.50	0.50	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.50	1.00	0.00	0.000
FCF Positive Streak	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Earnings Persistence	—	—	—	—	—	0.50	0.50	0.50	0.50	0.99	0.88	0.89	0.83	0.93	0.95	0.96	0.50	0.50	0.96	0.98	0.981
Earnings Smoothness	—	0.00	0.00	0.00	0.14	0.00	0.00	0.00	0.00	0.97	0.66	0.68	0.46	0.79	0.88	0.90	0.55	0.59	0.91	0.95	0.952
ROE Trend	—	—	—	—	—	—	0.35	0.29	0.22	-0.10	-0.04	-0.07	-0.16	-0.34	-0.14	-0.15	-0.10	-0.04	-0.07	-0.10	-0.096
Gross Margin Trend	—	—	—	—	—	-0.01	-0.01	-0.01	-0.01	-0.01	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.01	-0.02	-0.023
FCF Margin Trend	—	—	—	—	—	0.16	0.08	0.06	0.04	-0.01	0.05	-0.00	-0.02	-0.03	-0.05	-0.04	0.01	0.04	0.06	0.06	0.063
Sustainable Growth Rate	23.9%	27.3%	24.4%	34.3%	41.0%	1.1%	61.6%	64.3%	68.0%	51.2%	16.9%	19.0%	13.7%	15.5%	25.8%	27.1%	32.1%	33.0%	20.8%	19.0%	19.04%
Internal Growth Rate	5.7%	4.6%	8.7%	12.8%	15.6%	56.7%	48.8%	52.0%	56.7%	37.4%	11.0%	12.5%	8.7%	10.0%	19.1%	20.3%	25.0%	25.8%	16.2%	14.7%	14.71%

Cash Flow Quality

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
OCF/Net Income	2.13	6.09	2.85	2.36	2.25	1.00	0.80	0.83	0.81	1.12	1.70	1.51	1.86	1.80	1.51	1.46	1.43	1.60	2.19	2.35	2.348
FCF/OCF	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.99	0.99	1.00	1.00	1.00	1.00	0.999
FCF/Net Income	snapshot only																				2.347
OCF/EBITDA	snapshot only																				1.466
CapEx/Revenue	0.1%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%	0.1%	0.0%	0.0%	0.02%
CapEx/Depreciation	snapshot only																				0.007
Accruals Ratio	-0.06	-0.22	-0.15	-0.15	-0.17	0.00	0.07	0.06	0.07	-0.03	-0.12	-0.09	-0.13	-0.13	-0.08	-0.08	-0.09	-0.12	-0.17	-0.17	-0.173
Sloan Accruals	snapshot only																				0.198
Cash Flow Adequacy	snapshot only																				1878.967
Earnings Quality Score	snapshot only																				0.750

Dividends & Buybacks

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.9%	2.9%	3.2%	2.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Dividend/Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.94	$0.96	$0.96	$0.95	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Payout Ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	42.9%	40.1%	48.1%	45.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
FCF Payout Ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	25.2%	26.6%	26.0%	25.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Total Payout Ratio	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	33.5%	1.2%	1.1%	1.4%	86.1%	0.2%	1.0%	0.7%	0.7%	0.8%	0.0%	0.00%
Div. Increase Streak	—	—	—	—	—	—	—	—	—	—	0	0	0	0	—	—	—	—	—	—	—
Chowder Number	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Buyback Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.5%	5.3%	5.2%	5.8%	2.2%	0.0%	0.1%	0.1%	0.1%	0.1%	0.0%	0.00%
Net Buyback Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.5%	5.3%	5.2%	5.8%	2.2%	0.0%	0.1%	-0.0%	-0.1%	-0.2%	-0.4%	-0.36%
Total Shareholder Return	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.5%	8.2%	8.1%	9.0%	4.5%	0.0%	0.1%	-0.0%	-0.1%	-0.2%	-0.4%	-0.36%

DuPont Factors

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Tax Burden (NI/EBT)	0.92	0.92	0.92	0.91	0.87	1.83	1.73	1.59	1.49	0.85	0.74	0.73	0.70	0.70	0.76	0.77	0.80	0.81	0.74	0.74	0.737
Interest Burden (EBT/EBIT)	0.45	0.31	1.06	1.11	1.15	1.13	0.87	0.87	0.87	0.89	0.83	0.85	0.84	0.86	0.92	0.92	0.93	0.95	0.95	0.95	0.950
EBIT Margin	0.24	0.15	0.12	0.15	0.16	0.19	0.27	0.29	0.31	0.37	0.36	0.36	0.30	0.30	0.29	0.29	0.31	0.29	0.26	0.23	0.231
Asset Turnover	0.55	1.01	0.71	0.77	0.85	0.93	0.79	0.85	0.90	0.98	0.78	0.83	0.88	0.92	0.79	0.82	0.85	0.91	0.76	0.79	0.792
Equity Multiplier	4.39	6.24	3.03	3.03	3.03	3.03	1.88	1.88	1.88	1.88	1.71	1.71	1.71	1.71	1.61	1.61	1.61	1.61	1.48	1.48	1.485

Per Share

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
EPS (Diluted TTM)	$0.40	$0.20	$0.57	$0.80	$0.95	$2.54	$2.94	$3.09	$3.30	$2.48	$2.19	$2.39	$2.00	$2.11	$2.50	$2.61	$3.10	$3.16	$2.70	$2.48	$2.48
Book Value/Share	$1.66	$1.68	$3.09	$3.08	$3.06	$3.05	$6.54	$6.58	$6.63	$6.64	$7.93	$8.11	$8.12	$8.04	$11.32	$11.26	$11.28	$11.23	$14.83	$14.81	$15.74
Tangible Book/Share	$-1.11	$-1.13	$0.71	$0.70	$0.70	$0.70	$3.93	$3.95	$3.98	$3.99	$5.61	$5.73	$5.73	$5.68	$9.38	$9.33	$9.34	$9.30	$13.30	$13.28	$13.28
Revenue/Share	$4.02	$4.69	$5.06	$5.46	$5.98	$6.55	$7.11	$7.70	$8.21	$8.93	$9.89	$10.72	$11.40	$11.74	$12.28	$12.73	$13.22	$14.07	$14.80	$15.30	$15.55
FCF/Share	$0.84	$1.23	$1.63	$1.89	$2.14	$2.53	$2.34	$2.58	$2.65	$2.79	$3.72	$3.61	$3.70	$3.79	$3.76	$3.78	$4.43	$5.06	$5.93	$5.82	$5.91
OCF/Share	$0.84	$1.23	$1.63	$1.90	$2.14	$2.54	$2.34	$2.58	$2.66	$2.79	$3.73	$3.61	$3.71	$3.80	$3.78	$3.80	$4.44	$5.07	$5.93	$5.82	$5.91
Cash/Share	$3.90	$3.96	$3.88	$3.87	$3.85	$3.83	$5.24	$5.28	$5.32	$5.32	$6.01	$6.14	$6.14	$6.08	$8.02	$7.98	$8.00	$7.96	$13.21	$13.19	$11.08
EBITDA/Share	$1.22	$1.02	$0.90	$1.12	$1.29	$1.59	$2.33	$2.62	$2.93	$3.70	$3.94	$4.25	$3.84	$3.93	$4.01	$4.07	$4.54	$4.53	$4.28	$3.97	$3.97
Debt/Share	$3.32	$3.37	$3.25	$3.23	$3.21	$3.20	$3.11	$3.13	$3.15	$3.16	$3.29	$3.36	$3.36	$3.33	$3.12	$3.10	$3.10	$3.09	$4.08	$4.08	$4.08
Net Debt/Share	$-0.59	$-0.60	$-0.64	$-0.64	$-0.63	$-0.63	$-2.13	$-2.15	$-2.16	$-2.17	$-2.72	$-2.78	$-2.78	$-2.75	$-4.91	$-4.88	$-4.89	$-4.87	$-9.13	$-9.12	$-9.12

Academic Models

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Altman Z-Score	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	4.503
Altman Z-Prime	snapshot only																				9.196
Piotroski F-Score	4	8	7	8	7	6	5	5	6	6	6	6	7	6	8	7	7	7	6	6	6
Beneish M-Score	—	-0.55	-2.63	-2.74	-2.81	-2.01	-1.51	-1.57	-1.52	-1.90	-2.56	-2.47	-2.64	-2.65	-2.64	-2.65	-2.69	-2.79	-3.12	-3.07	-3.073
Ohlson O-Score	snapshot only																				-10.482
ROIC (Greenblatt)	snapshot only																				31.50%
Net-Net WC	snapshot only																				$8.60
EVA	snapshot only																				$106229695.44

Credit

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Credit Rating	snapshot only																				AA+
Credit Score	51.98	56.88	66.89	74.05	79.72	79.93	89.80	89.46	89.73	90.99	90.83	90.76	90.98	92.77	94.62	94.51	95.08	94.67	95.00	91.57	91.573
Credit Grade	snapshot only																				2
Credit Trend	snapshot only																				-2.937
Implied Spread (bps)	snapshot only																				65.000
Industry Credit Rank	snapshot only																				90
Sector Credit Rank	snapshot only																				85

HRMY NASDAQ

Edge Score

Analyst Insights

Financial Rating

InsiderStreet Scorecard

Risk & Quality Signals

Valuation

DuPont Decomposition (5-Factor)

Graham-Dodd Adjusted Valuation

Profitability Trends

Leverage & Solvency Trends

Efficiency & Working Capital Trends

Growth Trends (YoY %)

Earnings Stability

Monte Carlo Price Simulation

Executive Compensation

C-Suite Compensation

CEO Pay Ratio

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Scaling Efficiency

Sign in to InsiderStreet